For stage I‐III cancer patients, either a RAS or BRAF mutation was detected in 24/56 (42.9%) of requested LPs; for stage I–II patients, LP was positive in 9/22 (40.9%) of cases, and in 1/5 (20%) of cases for stage I. Here, BRAF is linked to cancer.